FDA Sets March 16, 2027 Decision Date For Aquestive's Resubmitted Anaphylm Application

The agency accepted the resubmission as a Class 2 response, and Aquestive still plans a Canadian filing in the fourth quarter.

Share
FDA Sets March 16, 2027 Decision Date For Aquestive's Resubmitted Anaphylm Application

The FDA has accepted Aquestive Therapeutics' resubmitted application for Anaphylm, its under-the-tongue epinephrine film, and set a March 16, 2027 goal date for a decision, according to an 8-K filed Thursday. The agency had rejected the first application in a January letter.

What the 8-K says

The FDA acknowledged the resubmission as complete and assigned a Prescription Drug User Fee Act goal date, the agency's target date for a decision, of March 16, 2027. The date follows the FDA's classification of the resubmission as a Class 2 response, the company said in its press release.

Aquestive submitted the resubmission on September 16, 2026. It followed positive topline results announced in August 2026 from human factors and pharmacokinetic studies, run to address items in the FDA's Complete Response Letter of January 30, 2026. That letter is the FDA's formal rejection of the first application.

CEO Daniel Barber said the acceptance and a Class 2 date "as expected gives us a clear path forward for Anaphylm." He said the company is advancing commercial preparations in parallel, "if approved."

What it changes

The resubmission now has a dated finish line. The company says Anaphylm, a sublingual film for Type I allergic reactions including anaphylaxis, would be the first and only oral rescue medication for severe allergic reactions if approved.

The FDA trade name for the product, Anaphylm, has been conditionally approved, a status the company first reported in an 8-K filed May 13. Final approval of the name depends on approval of the product.

The company's risk language names the possibilities that the FDA could disagree with its reading of the study results, ask for more studies, or consider issues raised in citizen petitions. It also lists government shutdowns and resource limits at the agency as risks to timely review.

What to watch

Aquestive says it remains on track to complete a New Drug Submission to Health Canada in the fourth quarter of 2026.

Mr. Barber said the company aims to complete the FDA review "on or before our assigned goal date" of March 16, 2027.

Sources

More on Aquestive Therapeutics

All Aquestive Therapeutics (AQST) coverage →